Skip to main content

D9103C00001 A Phase III, Randomized, Placebo-=controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-

NCT03833154

A Phase III, Randomized, Placebo-=controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

AstraZeneca

AstraZeneca AB is doing this research to find out if the medication called durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy.

This study is currently enrolling.